In-Office Use of Amniotic Membrane

Human amniotic membrane (AM) has been shown to provide a substantial benefit in treating certain types of conjunctival and corneal disease. While AM has traditionally been transplanted using sutures or fibrin glue in an operating room, the in-office application of sutureless AM is emerging as a less invasive alternative with promising clinical outcomes. In-office availability of AM allows clinicians to treat a variety of ocular surface conditions rapidly and effectively.

What Is Amniotic Membrane?

Amniotic membrane is an avascular fetal membrane that lies deep to the chorion and is harvested in a sterile environment from placental tissue obtained during elective cesarean sections. Donors are screened for transmissible diseases, and the AM is further treated with broad-spectrum antibiotics immediately after collection.

AM is made up of three layers: epithelium, basement membrane, and stroma. Several types of collagen make up the basement membrane, including type VII collagen, which is also present in the conjunctival and corneal basement membranes. The stroma of AM can be subdivided further into a compact layer, a fibroblast layer, and an outer spongy layer.1

Beneficial properties of AM. Several characteristics contribute to the efficacy of AM in treating ocular surface problems. First, AM acts as a physical barrier to protect conjunctival and corneal epithelium as it heals, and it reduces pain caused by friction of the eyelids over the surface. In addition, the AM basement membrane promotes epithelial growth through cell migration, adhesion, and differentiation, while also inhibiting cell death.2,3 Furthermore, the stroma of AM, which contains fetal hyaluronic acid, inhibits fibroblast growth and reduces inflammation through decreased expression of cytokines.

Research has also shown AM to block angiogenesis and have antimicrobial properties.1 The mechanism of the antimicrobial effect is controversial, but AM may decrease the risk of infection either through inherent chemical properties or through its function as a physical barrier.

AM is universally tolerated due to its lack of histocompatibility antigens HLA-A, B, or DR; it can be implanted without concern for rejection.

Types of Amniotic Membrane

Currently, two main types of AM are commercially available for in-office use: cryopreserved and dehydrated. Both types come in a variety of tissue thicknesses and sizes, depending on clinical needs.

Cryopreserved AM. Cryopreservation of AM involves slow freezing at –80°C using DMEM/glycerol preservation media to allow for slow-rate freezing without ice formation. This preservation technique retains the extracellular matrix components, such as heavy-chain hyaluronic acids, growth factors, fibronectin, and collagen, all of which promote anti-inflammatory effects and healing. The tissue is stored in a –80°C freezer and brought to room temperature when needed for use.

Types of Vision Care Networks

Among the top of the technology companys rises EyeCyte which connects consumers looking for cutting edge technology and science to help find doctors who are able to provide much-needed services. Doctors : Join the Eye Doctor Referal Network 


Placement of amniotic membrane on the ocular surface; without sutures for Chronic Dry Cye

These doctors are using CPT code 65778 for In-Office “Placement of amniotic membrane on the ocular surface; without sutures” per 2018


References from 2018 back:

Major investments into Ocular prior to 2018

EyeCyte | Crunchbase › organization › eyecyte


EyeCyte is engaged in the development of therapeutics for the treatment of neovascular and degenerative retinal diseases. … EyeCyte, Inc. is working with Pfizer’s Bioinnovation and io therapeutics Center and The Scripps Research Institute to develop novel therapeutics to treat …
EyeCyte Competitors, Revenue and Employees – Owler … › company › eyecyte
The top 10 competitors in EyeCyte’s competitive set are Biotech Visioncare, VisionCare, Trivitron, Quest Medical, Marco, InSite Vision, Ocata Therapeutics, …
EyeCyte , Inc. – Overview, News & Competitors | › eyecyte-inc


View EyeCyte , Inc. ( location in California, United States , revenue, industry and description. Find related and similar companies as well as …
EyeCyte | Company | RadialReport › firms
EyeCyte is engaged in the development of therapeutics for the treatment of neovascular and degenerative retinal diseases. EyeCyte, Inc. is working with Pfizer’s …
EyeCyte, Inc. Secures Series A Funding from Pfizer | Business … › news › home › EyeCyte-Secures-Series-Fun…
Jun 23, 2008 – EyeCyte, Inc., an early stage stem/progenitor cell-based ophthalmology research and development company based in La Jolla, California, …
EyeCyte – CB Insights › company › eyecyte


EyeCyte is a Healthcare/Biotechnology company based in La Jolla, California. EyeCyte’sinvestors include Pfizer Venture Investments and Pfizer Strategic In.
EyeCyte-Receives-$3-Million | VentureDeal › EyeCyte-Receives-$3-Million › Default


Jun 23, 2008 – Company Description, EyeCyte, Inc., an early stage ophthalmology research and development company based in La Jolla, California, …
EyeCyte Obtains $3M from Pfizer through Series A Round … › News
Jun 23, 2008 – Agreement makes Pfizer an exclusive partner and gives it an advisory and board role. EyeCyte secured a $3 million series A financing through …